Nervous Disorder TRIZ Cases

Formula I-A and I-B compounds act as selective protonophores to increase energy expenditure.

ApoE-functionalized lipid nanoparticles bypass blood-brain barrier limitations to selectively transfect inflammatory microglia.

Alkaline extraction yields over 90 percent purity, overcoming the trade-off between total hydroxystilbene content and manufacturing precision.

LKKTETQ polypeptide increases CD4 and CD8 white blood cell counts to enhance immune response against HIV infection.

High-dose intranasal insulin bypasses the blood-brain barrier to reduce brain damage in neonates with hypoxic-ischemic encephalopathy.

A tissue-engineered rostral migratory stream guides neuroblast migration to injured brain regions.

Helical peptoids with arylalkyl groups block neurotoxic aggregates, addressing ineffective Alzheimer's treatments.

PIKFYVE kinase inhibitors modulate endosomal trafficking, reducing neuronal hyperexcitability and rescuing motor neuron survival in C9ORF72-linked ALS and FTD.

Codon-optimized GBA polynucleotides boost stable GCase expression in patient cells, reducing lifelong injection burdens for Gaucher disease therapy.

XTEN fusion proteins extend growth hormone serum half-life without manufacturing complexity or immunogenicity.

Synthesizing non-solvated crystals of N-(2-aminophenyl)-6-(7-methoxyquinoline-4-oxy)-1-naphthamide via controlled cooling and drying.

Administering whey protein isolate before injury builds glutathione reserves, addressing the failure of post-injury therapies to prevent cognitive deficits.

A synergistic nutritional composition combines AMPA receptor antagonists with NRF2 activators to regulate neuronal activity.

Histidine hydrochloride buffer and carbohydrate protect recombinant lentiviral vectors from protein denaturation during ultra-low temperature storage.

Agomelatine sulphonic acid co-crystals resolve low solubility bottlenecks by establishing stable 2:1 stoichiometric phases that boost bioavailability.

Transgenic mice produce heavy chain-only antibodies lacking light chains, reducing manufacturing costs while maintaining serum stability.

A hepatic encephalopathy grading system classifies episodes using specific clinical criteria like disorientation and asterixis.

Opuntia ficus-indicia mucilage extracts bind amyloid beta peptides to disrupt fibril formation and aggregation pathways.

Physical forces replace cytokine cocktails to resolve heterogeneity in dendritic cell production, ensuring predictable therapeutic outcomes.

Nerve growth factor eye-drops transport molecules through the ocular surface to reach brain tissues.

A compound drug combines a STING activator with an ENPP1 inhibitor to enhance immune anti-tumor effects.

Benzimidazole derivatives target PIM1-3 and DYRK1A kinases to address the lack of effective treatments for leukemias and autoimmune disorders.

Fasudil treats depression and anxiety via rho kinase inhibition, bypassing neurotransmitter pathways to reduce side effects.

Antibodies recognize distinct Tau epitopes to block oligomerization, resolving the trade-off between high binding specificity and structural complexity.

Bifunctional PROTAC compounds recruit endogenous RIPK1 kinase to E3 ubiquitin ligases.

Radiolabeled amyloid binding compounds traverse the blood-brain barrier to detect neurodegenerative pathology.

Novel GPR84 antagonists with optimized heterocyclic structures overcome limited efficacy of existing drugs to treat multiple sclerosis and arthritis.

Selective inhibition of soluble TNF-α by a dominant negative protein reduces brain inflammation without causing demyelination.

Peptide epitopes derived from tumor cells bind MHC molecules to elicit specific T-cell responses, reducing side effects in small cell lung cancer treatment.

Soft ROCK inhibitors use ester hydrolysis to convert into inactive metabolites, ensuring targeted therapeutic action at the disease site.

Modified virus-like particles induce antibodies that block viral hemagglutination.

Oily suspension of ropivacaine, benzyl alcohol, and soybean oil extends analgesia duration while reducing cardiac and neural toxicity.

BT061 activates regulatory T cells to reduce adverse events and immunogenicity in autoimmune disease therapy.

TGF-beta inhibitors prevent spine ossification by blocking TGF-beta signaling, reducing fibrotic scar volume after spinal cord injury.

Segmentation of Tau into specific epitopes like PHF6 enables precise antibody targeting that resolves development complexity while inhibiting aggregation.

Formula 1 compounds modulate TRPC6 activity to treat hypertension, renal disease, and cancer by restoring cellular homeostasis.

Segmentation separates targeting and effector domains in cytotoxic proteins, resolving the trade-off between high potency and untargeted toxicity.

GM604 modulates TDP-43, SOD1, and Tau biomarkers to address inadequate single-target ALS treatments.

Compounds modulate APP processing to remove amyloid deposits, addressing limited cognitive improvement in mild cognitive impairment.

Recombinant adeno-associated virus vectors deliver anti-CGRP antibodies to sustain therapeutic levels, reducing migraine treatment burden.

Optimized excipient ratios in the orally disintegrating tablet improve storage stability and dissolution rate of memantine and melatonin.

Reducing adverse reactions and QT prolongation by capping deutetrabenazine doses when co-administered with strong CYP2D6 inhibitors.

Botanical extracts target COX and 5-lipoxygenase enzymes, reducing pro-inflammatory cytokines while avoiding side effects of conventional drugs.

Single-stranded oligonucleotides recruit RNase H to degrade OGG1 mRNA, reducing toxic trinucleotide repeat expansion in disease management.

Combining apilimod with glutamatergic agents modulates glutamate pathways to address ineffective symptom management in neurological diseases.

Paeonia lactiflora and Glycyrrhiza uralensis reduce reactive oxygen species to delay spinocerebellar ataxia progression.